TD Cowen Reaffirms Their Buy Rating on Sarepta Therapeutics (SRPT)
In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price ...
The Value of Moderna's mRNA Technology Is Obscured by Fears of a Hostile US Regulatory Environment
Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...
Exploring 3 High Growth Tech Stocks In The US Market
In the last week, the United States market has been flat, but over the past 12 months, it has risen by 8.4%, with earnings expected to grow by 14% per annum in the coming years. In this environment, ...
Exploring US High Growth Tech Stocks In April 2025
The United States market has experienced a flat performance over the last week, yet it has seen an 8.4% rise over the past year, with earnings forecasted to grow by 14% annually. In this context of ...